US20070260087A1 - Process of Preparing Esters and Ethers of Probucol and Derivatives Thereof - Google Patents

Process of Preparing Esters and Ethers of Probucol and Derivatives Thereof Download PDF

Info

Publication number
US20070260087A1
US20070260087A1 US11/578,871 US57887105A US2007260087A1 US 20070260087 A1 US20070260087 A1 US 20070260087A1 US 57887105 A US57887105 A US 57887105A US 2007260087 A1 US2007260087 A1 US 2007260087A1
Authority
US
United States
Prior art keywords
compound
optionally substituted
alkyl
acyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/578,871
Inventor
M. Weingarten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atherogenics Inc
Original Assignee
Atherogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atherogenics Inc filed Critical Atherogenics Inc
Priority to US11/578,871 priority Critical patent/US20070260087A1/en
Publication of US20070260087A1 publication Critical patent/US20070260087A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil

Definitions

  • the invention provides processes for the preparation of derivatives of probucol and, more specifically, to the preparation of ester and ether derivatives of probucol and derivatives thereof.
  • the present invention provides a process for preparing substituted compounds which are useful as medicinal agents, particularly as atherogenic agents and as agents useful in the areas of post-percutaneous coronary intervention restenosis, atherosclerosis, and other cardiovascular or inflammatory diseases and disorders.
  • U.S. Pat. No. 6,323,359 discloses and claims methods of manufacturing a group of probucol derivative compounds found in the '250 patent.
  • the '359 patent discloses the use of alkali metal hydroxide, alkali metal alkoxide, alkali ammonium alkoxide, and alkyl ammonium hydroxide to form alkali metal salts of the probucol derivative compounds and then reacting the salts with a dicarboxylic acid anhydride.
  • the invention includes a process for the manufacturing of a compound of Formula I or its ester or salt thereof, wherein Z 1 , Z 2 , Z 3 , and Z 4 are independently selected from the group consisting of hydrogen and alkyl, said alkyl optionally substituted by hydroxy, alkyl, alkenyl, acyl, nitro, amino, halo, carboxy and cyano; Z 5 and Z 6 are the same or different and independently selected from the group consisting of alkyl, alkenyl, and aryl all of which can be optionally substituted by hydroxy, alkyl, alkenyl, acyl, nitro, amino, halo, carboxy and cyano; Z 5 and Z 6 can come together to form a carbocyclic ring; M is selected from the group consisting of hydrogen, an optionally substituted unsaturated alkyl having from 1 to 10 carbon atoms, and an optionally substituted saturated alkyl having from 1 to 10 carbon atoms, said optionally substituted unsaturated alkyl and
  • alkyl or “alk”, alone or in combination, unless otherwise specified, means a saturated straight or branched primary, secondary, or tertiary hydrocarbon from 1 to 16 carbon atoms, including, but not limited to methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, and sec-butyl.
  • the alkyl group may be optionally substituted where possible with any moiety that does not otherwise interfere with the reaction or that provides an improvement in the process, including but not limited to halo, haloalkyl, hydroxyl, carboxyl, acyl, aryl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, phosphonate, either unprotected, or protected as necessary, as known to those skilled
  • C 1 -C 10 alkyl (or C 1-10 alkyl) is considered to include, independently, each member of the group, such that, for example, C 1 -C 10 alkyl includes straight, branched and where appropriate cyclic C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 and C 10 alkyl functionalities.
  • C(alkyl range) independently includes each member of that class as if specifically and separately set out.
  • the term “C 1-10 ” independently represents each species that falls within the scope, including, but not limited to, methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, iso-butyl, tert-butyl, pentyl, iso-pentyl, neo-pentyl, cyclopentyl, cyclopentyl, hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 3-ethylbutyl, 4-ethyl butyl, cyclohexyl, heptyl, 1-methylhexyl, 2-methylhexyl, 3-methylhexyl
  • alkenyl means a non-cyclic alkyl of 2 to 10 carbon atoms having one or more unsaturated carbon-carbon bonds.
  • the alkenyl group may be optionally substituted where possible with any moiety that does not otherwise interfere with the reaction or that provides an improvement in the process, including but not limited to halo, haloalkyl, hydroxyl, carboxyl, acyl, aryl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide
  • alkynyl means a non-cyclic alkyl of 2 to 10 carbon atoms having one or more triple carbon-carbon bonds, including but not limited to ethynyl and propynyl.
  • the alkynyl group may be optionally substituted where possible with any moiety that does not otherwise interfere with the reaction or that provides an improvement in the process, including but not limited to halo, haloalkyl, hydroxyl, carboxyl, acyl, aryl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphinyl,
  • aryl alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such rings may be attached together in a pendent manner or may be fused.
  • the “aryl” group can be optionally substituted where possible with one or more of the moieties selected from the group consisting of alkyl, alkenyl, alkynyl, heteroaryl, heterocyclic, carbocycle, alkoxy, oxo, aryloxy, arylalkoxy, cycloalkyl, tetrazolyl, heteroaryloxy; heteroarylalkoxy, carbohydrate, amino acid, amino acid esters, amino acid amides, alditol, halogen, haloalkylthi, haloalkoxy, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, aminoalkyl, aminoacyl, amido, alkylamino, dialkylamino, arylamino, nitro
  • acyl alone or in combination, means a group of the formula —C(O)R′, wherein R′ is alkyl, alkenyl, alkynyl, aryl, or aralkyl group.
  • halo and “halogen” and “halide”, alone or in combination, means chloro, bromo, iodo and fluoro.
  • amino alone or in combination, means a group of the formula NR′R′′, wherein R′ and R′′ are independently selected from a group consisting of a bond, hydrogen, alkyl, aryl, alkaryl, and aralkyl, wherein said alkyl, aryl, alkaryl and aralkyl may be optionally substituted where possible as defined above.
  • nitro alone or in combination, denotes the radical —NO 2 .
  • substituted means that one or more hydrogen on the designated atom or substituent is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and the that the substitution results in a stable compound.
  • a substitutent is “oxo” (keto) (i.e., ⁇ O)
  • 2 hydrogens on the atom are replaced.
  • an appropriate substituent known by those skilled in art may be substituted, including, but not limited to, hydroxyl, alkyl, alkenyl, acyl, nitro, protected amino, halo, protected carboxy, epoxide, and cyano.
  • polar or charged functionality means a polar or charged group attached in place of one or more hydrogen atoms.
  • Non limiting examples include carboxy, hydroxy, amino, epoxide, etc.
  • protecting group or “protected” means a substituent that protects various sensitive or reactive groups present, so as to prevent said groups from interfering with a reaction. Such protection may be carried out in a well-known manner as taught by Greene, T. M. and Wuts, P. G. M., in Protective Groups in Organic Synthesis , John Wiley and Sons, Third Edition, 1999; Kocienski, P. J., in Protecting Groups , Thieme Medical Publications, 2 nd Edition, 2000; or similar texts. The protecting group may be removed after the reaction in any manner known by those skilled in the art.
  • Non-limiting examples of protecting groups include trimethylsilyl, dimethylhexylsilyl, t-butyldimethylsilyl, and t-butyldiphenylsilyl, trityl or substituted trityl, alkyl groups, acyl groups such as acetyl and propionyl, methanesulfonyl, and p-toluenesulfonyl.
  • a protected carboxy could be selected from one of the following:
  • acid anhydride and “carboxylic acid anhydride”, alone or in combination means compounds having the formulas acyl-OC(O)R ⁇ , acyl-OC(O)OR ⁇ , acyl-OC(O)SR ⁇ , or acyl-OC(O)NR ⁇ R ⁇ wherein R ⁇ is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, and aralkyl and R ⁇ is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, alkaryl, aralkyl and a protecting group (as that term is defined herein).
  • the terms also include compounds having the formula wherein Z is selected from alkyl, alkenyl, alkynyl, aryl, aralkyl and —(CH 2 )NR ⁇ . All “carboxylic acid anhydrides” and “acid anhydrides” may optionally be substituted as defined herein.
  • activated carboxylic acid ester means compounds having the formula C(O)SR′′ and C(O)OR′′, wherein R′′ is a substituted or unsubstituted aryl or an unsubstituted or substituted alkyl.
  • epoxide means the radical wherein all R groups are independently selected from hydrogen, alkyl, aryl and arylalkyl wherein said alkyl, aryl and arylalkyl may optionally be substituted with a polar functionality.
  • esters of probucol and “esters of probucol derivatives” are defined as probucol or probucol derivatives (as the case may be) wherein one or both of the phenol moieties are acylated.
  • the term “monoesters of probucol” is defined as probucol wherein one of the phenol moieties are acylated.
  • the term “diesters of probucol” is defined as probucol wherein both of the phenol moieties are acylated.
  • ethers of probucol and “ethers of probucol derivatives” are defined as probucol or probucol derivatives (as the case may be) wherein one or both of the phenol moieties are alkylated.
  • probucol derivative refers to the compound wherein at least one Z 1 , Z 2 , Z 3 , and Z 4 is other than t-butyl and/or one or both of Z 5 and Z 6 are other than methyl and/or one or both of M and J are other than hydrogen.
  • the present invention is concerned with processes for preparing compounds of Formula I, which are useful as medicinal agents, particularly (but not limited to) in the areas of post-percutaneous coronary intervention restenosis, atherosclerosis and other inflammatory diseases or disorders.
  • the invention encompasses the method of manufacturing a compound of Formula I or its ester or salt thereof, wherein Z 1 , Z 2 , Z 3 , and Z 4 are independently selected from the group consisting of hydrogen and alkyl, said alkyl optionally substituted by hydroxy, alkyl, alkenyl, acyl, nitro, amino, halo, carboxy and cyano; Z 5 and Z 6 are the same or different and independently selected from the group consisting of alkyl, alkenyl, and aryl all of which can be optionally substituted by hydroxy, alkyl, alkenyl, acyl, nitro, amino, halo, carboxy and cyano; Z 5 and Z 6 can come together to form a carbocyclic ring; M is selected from the group consisting of hydrogen, an optionally substituted unsaturated alkyl having from 1 to 10 carbon atoms, and an optionally substituted saturated alkyl having from 1 to 10 carbon atoms, said optionally substituted unsaturated
  • the invention is represented by the process to manufacture a compound of Formula I or its ester or salt thereof, wherein Z 1 , Z 2 , Z 3 , and Z 4 are independently selected from the group consisting of hydrogen and alkyl, said alkyl optionally substituted by hydroxy, alkyl, alkenyl, acyl, nitro, amino, halo, carboxy and cyano; Z 5 and Z 6 are the same or different and independently selected from the group consisting of alkyl, alkenyl, and aryl all of which can be optionally substituted by hydroxy, alkyl, alkenyl, acyl, nitro, amino, halo, carboxy and cyano; Z 5 and Z 6 can come together to form a carbocyclic ring; M is selected from the group consisting of hydrogen, an optionally substituted unsaturated alkyl having from 1 to 10 carbon atoms, and an optionally substituted saturated alkyl having from 1 to 10 carbon atoms, said optionally substituted uns
  • the invention is represented by the process to manufacture a compound of Formula IV or its ester or salt thereof, wherein J is selected from the group consisting of an optionally substituted unsaturated alkyl having from 1 to 10 carbon atoms, and an optionally substituted saturated alkyl having from 1 to 10 carbon atoms, said optionally substituted unsaturated alkyl and optionally substituted saturated alkyl optionally containing a polar or charged functionality; the process comprising: reacting a compound of Formula V, with a compound of Formula III, wherein Y is R 2 or NR 2 R 5 ; R 1 , R 2 , R 3 and R 4 and R 5 are independently selected from an optionally substituted C 1 -C 10 alkyl or an optionally substituted C 2 -C 10 alkenyl; R 1 and R 2 can optionally come together to form a ring; R 3 and R 4 can optionally come together to form a ring; and a compound selected from the group consisting of a saturated or unsatur
  • the invention is represented by the process to manufacture a compound of Formula I or its ester or salt thereof, wherein Z 1 , Z 2 , Z 3 , and Z 4 are independently selected from the group consisting of hydrogen and alkyl, said alkyl optionally substituted by hydroxy, alkyl, alkenyl, acyl, nitro, amino, halo, carboxy and cyano; Z 5 and Z 6 are the same or different and independently selected from the group consisting of alkyl, alkenyl, and aryl all of which can be optionally substituted by hydroxy, alkyl, alkenyl, acyl, nitro, amino, halo, carboxy and cyano; Z 5 and Z 6 can come together to form a carbocyclic ring; M is selected from the group consisting of hydrogen, an optionally substituted unsaturated acyl having from 1 to 18 carbon atoms, and an optionally substituted saturated acyl having from 1 to 18 carbon atoms, said optionally substituted unsatur
  • the invention is represented by the process to manufacture a compound of Formula IV or its ester or salt thereof, wherein J is selected from the group consisting of an optionally substituted unsaturated acyl having from 1 to 18 carbon atoms and an optionally substituted saturated acyl having from 1 to 18 carbon atoms, said optionally substituted unsaturated acyl and optionally substituted saturated acyl optionally containing a polar or charged functionality; the process comprising: reacting a compound of Formula V, with a compound of Formula III, wherein Y is R 2 or NR 2 R 5 ; R 1 , R 2 , R 3 and R 4 and R 5 are independently selected from an optionally substituted C 1 -C 10 alkyl or an optionally substituted C 2 -C 10 alkenyl; R 1 and R 2 can optionally come together to form a ring; R 3 and R 4 can optionally come together to form a ring; and a compound selected from the group consisting of a saturated or unsaturated
  • the invention is represented by the process to manufacture a compound of Formula IV or its ester or salt thereof, wherein J is selected from the group consisting of an optionally substituted unsaturated acyl having from 1 to 18 carbon atoms and an optionally substituted saturated acyl having from 1 to 18 carbon atoms, said optionally substituted unsaturated acyl and optionally substituted saturated acyl optionally containing a polar or charged functionality; the process comprising: reacting a compound of Formula V, with a compound of Formula VI, wherein R 6 is selected from an optionally substituted C 1 -C 10 alkyl or an optionally substituted C 2 -C 10 alkenyl; m is an integer selected from 1 to 7; n is an integer selected from 1 to 7; and a compound selected from the group consisting of a saturated or unsaturated acyl halide, saturated or unsaturated carboxylic acid anhydride and a saturated or unsaturated activated carboxylic acid ester, all of which may optional
  • the invention is represented by the process to manufacture a compound of Formula IV or its ester or salt thereof, wherein J is selected from the group consisting of an optionally substituted unsaturated acyl having from 1 to 18 carbon atoms and an optionally substituted saturated acyl having from 1 to 18 carbon atoms, said optionally substituted unsaturated acyl and optionally substituted saturated acyl optionally containing a polar or charged functionality; the process comprising: reacting a compound of Formula V, with a compound of Formula VII, wherein m is an integer selected from 1 to 7; n is an integer selected from 1 to 7; and a compound selected from the group consisting of a saturated or unsaturated acyl halide, saturated or unsaturated carboxylic acid anhydride and a saturated or unsaturated activated carboxylic acid ester, all of which may optionally be substituted by one or more substituents selected from the group consisting of protected hydroxy, alkyl, alkenyl, acyl,
  • the invention is represented by the process to manufacture a compound of Formula IV or its ester or salt thereof, wherein J is selected from the group consisting of an optionally substituted unsaturated acyl having from 1 to 18 carbon atoms and an optionally substituted saturated acyl having from 1 to 18 carbon atoms, said optionally substituted unsaturated acyl and optionally substituted saturated acyl optionally containing a polar or charged functionality; the process comprising: reacting a compound of Formula V, with a compound of Formula VII, wherein m is an integer selected from 1 to 7; n is an integer selected from 1 to 7; and a compound selected from the group consisting of succinic acid anhydride, glutaric acid anhydride, adipic acid anhydride, suberic acid anhydride, sebacic acid anhydride, azelaic acid anhydride, phthalic acid anhydride, maleic acid anhydride, and acetic acid anhydride, all of which may optionally be substituted by
  • the invention is represented by the process to manufacture a compound of Formula VIII, IX or X or its ester or salt thereof, the process comprising: reacting a compound of Formula V, with a compound of Formula VII, wherein m is an integer selected from 1 to 7; n is an integer selected from 1 to 7; and a compound selected from the group consisting of succinic acid anhydride, glutaric acid anhydride, and acetic acid anhydride, all of which may optionally be substituted by one or more substituents selected from the group consisting of protected hydroxy, alkyl, alkenyl, acyl, nitro, protected amino, halo, protected carboxy and cyano; and separating and isolating said compound of Formula VIII, IX or X.
  • the invention is represented by the process to manufacture a compound of Formula VIII, IX or X or its ester or salt thereof, the process comprising: reacting a compound of Formula V, with a compound of Formula DBU or DBN, and a compound selected from the group consisting of succinic acid anhydride, glutaric acid anhydride, and acetic acid anhydride, all of which may optionally be substituted by one or more substituents selected from the group consisting of protected hydroxy, alkyl, alkenyl, acyl, nitro, protected amino, halo, protected carboxy and cyano; and separating and isolating said compound of Formula VIII, IX or X.
  • the invention is represented by the process to manufacture a compound of Formula VIII or its ester or salt thereof, the process comprising: reacting a compound of Formula V with a compound of Formula DBU, and succinic acid anhydride; separating and isolating the compound of Formula VIII.
  • the invention is represented by the process to manufacture a compound of Formula VIII or its ester or salt thereof, the process comprising: reacting a compound of Formula V with DBU and succinic acid anhydride; further comprising the addition of an alkaline carbonate; and separating and isolating the compound of Formula VIII.
  • compositions and methods are described in terms of “comprising” various components or steps, the compositions and methods can also “consist essentially of” or “consist of” the various components and steps.
  • Suitable solvents for carrying out the processes of the present disclosure are inert organic solvents, including but are not limited to, alcohols, aldehydes, amides, ethers, esters, halogenated solvents, hydrocarbons, glycols and glycol ethers, ketones, nitrites, and numerous other solvents common in chemical processes, as well as mixtures of such solvents.
  • inert solvents can be used alone or in combination, and can be miscible or immiscible with each other.

Abstract

The current patent application provides methods for manufacturing compounds of Formula I
Figure US20070260087A1-20071108-C00001
 wherein all substituents are described herein.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application claims priority to U.S. provisional patent application Ser. No. 60/564,267, filed Apr. 20, 2004.
    • FIELD OF THE INVENTION
  • The invention provides processes for the preparation of derivatives of probucol and, more specifically, to the preparation of ester and ether derivatives of probucol and derivatives thereof.
    • DESCRIPTION OF RELATED ART
  • The present invention provides a process for preparing substituted compounds which are useful as medicinal agents, particularly as atherogenic agents and as agents useful in the areas of post-percutaneous coronary intervention restenosis, atherosclerosis, and other cardiovascular or inflammatory diseases and disorders.
  • Several series of phenolic structural derivatives related to the probucol have been prepared and disclosed in the literature. U.S. Pat. No. 5,262,439 to Parthasarathy (issued Nov. 16, 1993), discloses analogs of probucol with increased water solubility in which one or both of the hydroxyl groups are replaced with ester groups that increase the water solubility of the compound. The '439 patent reports that carboxylic acid derivatives of probucol compounds (as that term is defined in the '439 patent) can be prepared by treating probucol compounds with an excess of dicarboxylic acid anhydride and catalytic amounts of 4-dimethylamino pyridine at a temperature sufficient to ensure that the dicarboxylic acid anhydride is liquid. According to the disclosure, no anhydrous solvent is necessary under these conditions, as the anhydride itself acts as a solvent.
  • In U.S. Pat. No. 6,147,250 (issued Nov. 14, 2000), compounds, compositions, methods for inhibiting the expression of VCAM-1, and methods of preparing such compounds and compositions are disclosed. The patent reports that monoesters of probucol can be prepared by treating probucol in tetrahydrofuran with sodium hydride and an acid chloride or acid anhydride. In one example using this process, a monoester of probucol is prepared in approximately 14% yield following purification by chromatographic methods.
  • U.S. Pat. No. 6,323,359 discloses and claims methods of manufacturing a group of probucol derivative compounds found in the '250 patent. The '359 patent discloses the use of alkali metal hydroxide, alkali metal alkoxide, alkali ammonium alkoxide, and alkyl ammonium hydroxide to form alkali metal salts of the probucol derivative compounds and then reacting the salts with a dicarboxylic acid anhydride.
  • A series of French patents have disclosed that certain probucol derivatives are hypocholesterolemic and hypolipemic agents: Fr 2.168.137 (bis-4-hydroxyphenylthioalkane esters); Fr 2140771 (tetralinyl phenoxy alkanoic esters of probucol); Fr 2.140.769 (benzofuryloxyalkanoic acid derivatives of probucol); Fr 2.134.810 (bis-(3-alkyl-5-alkyl-4-thiazole-5-carboxy)phenylthio)alkanes); Fr 2.133.024 (bis-(4-nicotinoyloxyphenylthio)propanes); and Fr 2.130.975 ((bis-(4-phenoxyalkanoyloxy)-phenylthio)alkanes). Most notable with regards to the production of probucol derivatives is French Patent Publication No. 2.168.137, which describes the production of diesters of probucol by reacting probucol with a halide or anhydride of an organic acid in an inert solvent with heat and in the presence of a base such as an alkaline hydroxide or carbonate, or a tertiary amine (e.g., triethylamine). The O-metal salt derivative of probucol is also suggested to be useful as the reaction intermediate.
  • U.S. patent application Ser. No. 10/757,664, filed Jan. 13, 2003, teaches processes for the preparation of esters and ethers of probucol by reacting probucol or a free hydroxyl-containing probucol derivative with a Grignard reagent or a lithium reagent to form a magnesium or lithium salt, followed by a reaction with an ester-forming or ether-forming compound.
  • It is thus an object of the present invention to provide a simple and efficient process for the preparation of a select group of compounds such as those described in U.S. Pat. Nos. 6,147,250; 6,323,359; and 5,262,439.
    • SUMMARY OF THE INVENTION
  • A facile process for the preparation of esters and ethers of probucol or probucol derivatives is provided.
  • The invention includes a process for the manufacturing of a compound of Formula I or its ester or salt thereof,
    Figure US20070260087A1-20071108-C00002
    wherein Z1, Z2, Z3, and Z4 are independently selected from the group consisting of hydrogen and alkyl, said alkyl optionally substituted by hydroxy, alkyl, alkenyl, acyl, nitro, amino, halo, carboxy and cyano;
    Z5 and Z6 are the same or different and independently selected from the group consisting of alkyl, alkenyl, and aryl all of which can be optionally substituted by hydroxy, alkyl, alkenyl, acyl, nitro, amino, halo, carboxy and cyano;
    Z5 and Z6 can come together to form a carbocyclic ring;
    M is selected from the group consisting of hydrogen, an optionally substituted unsaturated alkyl having from 1 to 10 carbon atoms, and an optionally substituted saturated alkyl having from 1 to 10 carbon atoms, said optionally substituted unsaturated alkyl and optionally substituted saturated alkyl optionally containing a polar or charged functionality;
    or M is selected from the group consisting of hydrogen, an optionally substituted unsaturated acyl having from 1 to 18 carbon atoms, and an optionally substituted saturated acyl having from 1 to 18 carbon atoms, said optionally substituted unsaturated acyl and optionally substituted saturated acyl optionally containing a polar or charged functionality;
    J is selected from the group consisting of an optionally substituted unsaturated alkyl having from 1 to 10 carbon atoms, and an optionally substituted saturated alkyl having from 1 to 10 carbon atoms, said optionally substituted unsaturated alkyl and optionally substituted saturated alkyl optionally containing a polar or charged functionality;
    or J is selected from the group consisting of an optionally substituted unsaturated acyl having from 1 to 18 carbon atoms and an optionally substituted saturated acyl having from 1 to 18 carbon atoms, said optionally substituted unsaturated acyl and optionally substituted saturated acyl optionally containing a polar or charged functionality; the process comprising:
    reacting a compound of Formula II,
    Figure US20070260087A1-20071108-C00003
    wherein Z1, Z2, Z3, Z4, Z5 and Z6 are as previously defined, with a compound of Formula III,
    Figure US20070260087A1-20071108-C00004
    wherein Y is R2 or NR2R5;
    R1, R2, R3 and R4 and R5 are independently selected from an optionally substituted C1-C10 alkyl or an optionally substituted C2-C10 alkenyl;
    R1 and R2 can optionally come together to form a ring;
    R3 and R4 can optionally come together to form a ring;
    and a compound selected from the group consisting of a saturated or unsaturated acyl halide, saturated or unsaturated carboxylic acid anhydride and a saturated or unsaturated activated carboxylic acid ester, all of which may optionally be substituted by one or more substituents selected from the group consisting of protected hydroxy, alkyl, alkenyl, acyl, nitro, protected amino, amino, halo, protected carboxy and cyano; or, a compound selected the group consisting of a saturated or unsaturated alkyl halide, saturated or unsaturated alkyl-O-sulfonyl alkyl, a saturated or unsaturated alkyl-O-sulfonyl aryl, a saturated or unsaturated alkyl-O-acyl, and a saturated or unsaturated epoxide, all of which may optionally be substituted by one or more substituents selected from the group consisting of protected hydroxy, alkyl, alkenyl, acyl, nitro, protected amino, halo, protected carboxy, epoxide and cyano; and, separating and isolating the compound of Formula I.
    • DEFINITIONS
  • The following definitions are provided in order to aid those skilled in the art in understanding the detailed description of the present invention.
  • The terms “alkyl” or “alk”, alone or in combination, unless otherwise specified, means a saturated straight or branched primary, secondary, or tertiary hydrocarbon from 1 to 16 carbon atoms, including, but not limited to methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, and sec-butyl. The alkyl group may be optionally substituted where possible with any moiety that does not otherwise interfere with the reaction or that provides an improvement in the process, including but not limited to halo, haloalkyl, hydroxyl, carboxyl, acyl, aryl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art.
  • Whenever a range of is referred to herein, it includes independently and separately every member of the range. As a nonlimiting example, the term “C1-C10 alkyl” (or C1-10 alkyl) is considered to include, independently, each member of the group, such that, for example, C1-C10 alkyl includes straight, branched and where appropriate cyclic C1, C2, C3, C4, C5, C6, C7, C8, C9 and C10 alkyl functionalities.
  • In the text, whenever the term “C(alkyl range)” is used, the term independently includes each member of that class as if specifically and separately set out. As a non-limiting example, the term “C1-10” independently represents each species that falls within the scope, including, but not limited to, methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, iso-butyl, tert-butyl, pentyl, iso-pentyl, neo-pentyl, cyclopentyl, cyclopentyl, hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 3-ethylbutyl, 4-ethyl butyl, cyclohexyl, heptyl, 1-methylhexyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 6-methylhexyl, 1-ethylpentyl, 2-ethylpentyl, 3-ethylpentyl, 4-ethylpentyl, 5-ethylpenyl, 1-propylbutyl, 2-propylbutyl, 3-propybutyl, 4-propylbutyl, cycloheptyl, octyl, 1-methylheptyl, 2-methylheptyl, 3-methylheptyl, 4-methylheptyl, 5-methylheptyl, 6-methylheptyl, 7-methylheptyl, 1-ethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 5-ethylhexyl, 6-ethylhextyl, 1-propylpentyl, 2-propylpentyl, 3-propypentyl, 4-propylpentyl, 5-propylpentyl, cyclooctyl, nonyl, cyclononyl, decyl, or cyclodecyl.
  • The term “alkenyl”, alone or in combination, means a non-cyclic alkyl of 2 to 10 carbon atoms having one or more unsaturated carbon-carbon bonds. The alkenyl group may be optionally substituted where possible with any moiety that does not otherwise interfere with the reaction or that provides an improvement in the process, including but not limited to halo, haloalkyl, hydroxyl, carboxyl, acyl, aryl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art.
  • The term “alkynyl”, alone or in combination, means a non-cyclic alkyl of 2 to 10 carbon atoms having one or more triple carbon-carbon bonds, including but not limited to ethynyl and propynyl. The alkynyl group may be optionally substituted where possible with any moiety that does not otherwise interfere with the reaction or that provides an improvement in the process, including but not limited to halo, haloalkyl, hydroxyl, carboxyl, acyl, aryl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art.
  • The term “aryl”, alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such rings may be attached together in a pendent manner or may be fused. The “aryl” group can be optionally substituted where possible with one or more of the moieties selected from the group consisting of alkyl, alkenyl, alkynyl, heteroaryl, heterocyclic, carbocycle, alkoxy, oxo, aryloxy, arylalkoxy, cycloalkyl, tetrazolyl, heteroaryloxy; heteroarylalkoxy, carbohydrate, amino acid, amino acid esters, amino acid amides, alditol, halogen, haloalkylthi, haloalkoxy, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, aminoalkyl, aminoacyl, amido, alkylamino, dialkylamino, arylamino, nitro, cyano, thiol, imide, sulfonic acid, sulfate, sulfonate, sulfonyl, alkylsulfonyl, aminosulfonyl, alkylsulfonylamino, haloalkylsulfonyl, sulfanyl, sulfinyl, sulfamoyl, carboxylic ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, thioester, thioether, oxime, hydrazine, carbamate, phosphonic acid, phosphate, phosphonate, phosphinate, sulfonamido, carboxamido, hydroxamic acid, sulfonylimide or any other desired functional group that does not inhibit the pharmacological activity of this compound, either unprotected, or protected as necessary, as known to those skilled in the art. In addition, adjacent groups on an “aryl” ring may combine to form a 5- to 7-membered saturated or partially unsaturated carbocyclic, aryl, heteroaryl or heterocyclic ring, which in turn may be substituted as above.
  • The term “acyl”, alone or in combination, means a group of the formula —C(O)R′, wherein R′ is alkyl, alkenyl, alkynyl, aryl, or aralkyl group.
  • The terms “carboxy”, “COOR” and “C(O)OH” are used interchangeably.
  • The terms “halo” and “halogen” and “halide”, alone or in combination, means chloro, bromo, iodo and fluoro.
  • The term “amino”, alone or in combination, means a group of the formula NR′R″, wherein R′ and R″ are independently selected from a group consisting of a bond, hydrogen, alkyl, aryl, alkaryl, and aralkyl, wherein said alkyl, aryl, alkaryl and aralkyl may be optionally substituted where possible as defined above.
  • The term “nitro”, alone or in combination, denotes the radical —NO2.
  • The term “substituted”, means that one or more hydrogen on the designated atom or substituent is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and the that the substitution results in a stable compound. When a substitutent is “oxo” (keto) (i.e., ═O), then 2 hydrogens on the atom are replaced. If the term is used without an indicating group, an appropriate substituent known by those skilled in art may be substituted, including, but not limited to, hydroxyl, alkyl, alkenyl, acyl, nitro, protected amino, halo, protected carboxy, epoxide, and cyano.
  • The term “polar or charged functionality” means a polar or charged group attached in place of one or more hydrogen atoms. Non limiting examples include carboxy, hydroxy, amino, epoxide, etc.
  • The terms “protecting group” or “protected” means a substituent that protects various sensitive or reactive groups present, so as to prevent said groups from interfering with a reaction. Such protection may be carried out in a well-known manner as taught by Greene, T. M. and Wuts, P. G. M., in Protective Groups in Organic Synthesis, John Wiley and Sons, Third Edition, 1999; Kocienski, P. J., in Protecting Groups, Thieme Medical Publications, 2nd Edition, 2000; or similar texts. The protecting group may be removed after the reaction in any manner known by those skilled in the art. Non-limiting examples of protecting groups include trimethylsilyl, dimethylhexylsilyl, t-butyldimethylsilyl, and t-butyldiphenylsilyl, trityl or substituted trityl, alkyl groups, acyl groups such as acetyl and propionyl, methanesulfonyl, and p-toluenesulfonyl. For example, a protected carboxy could be selected from one of the following:
    Figure US20070260087A1-20071108-C00005
  • The terms “acid anhydride” and “carboxylic acid anhydride”, alone or in combination means compounds having the formulas acyl-OC(O)Rα, acyl-OC(O)ORα, acyl-OC(O)SRα, or acyl-OC(O)NRαRβ wherein Rα is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, and aralkyl and Rβ is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, alkaryl, aralkyl and a protecting group (as that term is defined herein). The terms also include compounds having the formula
    Figure US20070260087A1-20071108-C00006
    wherein Z is selected from alkyl, alkenyl, alkynyl, aryl, aralkyl and —(CH2)NRβ. All “carboxylic acid anhydrides” and “acid anhydrides” may optionally be substituted as defined herein.
  • The term “activated carboxylic acid ester” means compounds having the formula C(O)SR″ and C(O)OR″, wherein R″ is a substituted or unsubstituted aryl or an unsubstituted or substituted alkyl.
  • The term “epoxide” means the radical
    Figure US20070260087A1-20071108-C00007
    wherein all R groups are independently selected from hydrogen, alkyl, aryl and arylalkyl wherein said alkyl, aryl and arylalkyl may optionally be substituted with a polar functionality.
  • The terms “1,8-Diazabicyclo[5.4.0]undec-7-ene”, “DBU” and the structure
    Figure US20070260087A1-20071108-C00008
    are used interchangeably.
  • The terms “1,5-Diazabicyclo[4.3.0]non-5-ene”, “DBN” and the structure
    Figure US20070260087A1-20071108-C00009
    are used interchangeably.
  • The terms “esters of probucol” and “esters of probucol derivatives” are defined as probucol or probucol derivatives (as the case may be) wherein one or both of the phenol moieties are acylated. The term “monoesters of probucol” is defined as probucol wherein one of the phenol moieties are acylated. The term “diesters of probucol” is defined as probucol wherein both of the phenol moieties are acylated.
  • The terms “ethers of probucol” and “ethers of probucol derivatives” are defined as probucol or probucol derivatives (as the case may be) wherein one or both of the phenol moieties are alkylated.
  • The term “probucol derivative” refers to the compound
    Figure US20070260087A1-20071108-C00010
    wherein at least one Z1, Z2, Z3, and Z4 is other than t-butyl and/or one or both of Z5 and Z6 are other than methyl and/or one or both of M and J are other than hydrogen.
  • The terms “probucol monosuccinate”, “MSP”, and the sturucture
    Figure US20070260087A1-20071108-C00011
    are used interchangeably.
  • The terms “probucol disuccinate”, “DSP”, and the structure
    Figure US20070260087A1-20071108-C00012
    are used interchangeably.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention is concerned with processes for preparing compounds of Formula I, which are useful as medicinal agents, particularly (but not limited to) in the areas of post-percutaneous coronary intervention restenosis, atherosclerosis and other inflammatory diseases or disorders.
  • In a broad description, the invention encompasses the method of manufacturing a compound of Formula I or its ester or salt thereof,
    Figure US20070260087A1-20071108-C00013
    wherein Z1, Z2, Z3, and Z4 are independently selected from the group consisting of hydrogen and alkyl, said alkyl optionally substituted by hydroxy, alkyl, alkenyl, acyl, nitro, amino, halo, carboxy and cyano;
    Z5 and Z6 are the same or different and independently selected from the group consisting of alkyl, alkenyl, and aryl all of which can be optionally substituted by hydroxy, alkyl, alkenyl, acyl, nitro, amino, halo, carboxy and cyano;
    Z5 and Z6 can come together to form a carbocyclic ring;
    M is selected from the group consisting of hydrogen, an optionally substituted unsaturated alkyl having from 1 to 10 carbon atoms, and an optionally substituted saturated alkyl having from 1 to 10 carbon atoms, said optionally substituted unsaturated alkyl and optionally substituted saturated alkyl optionally containing a polar or charged functionality;
    or M is selected from the group consisting of hydrogen, an optionally substituted unsaturated acyl having from 1 to 18 carbon atoms, and an optionally substituted saturated acyl having from 1 to 18 carbon atoms, said optionally substituted unsaturated acyl and optionally substituted saturated acyl optionally containing a polar or charged functionality;
    J is selected from the group consisting of an optionally substituted unsaturated alkyl having from 1 to 10 carbon atoms, and an optionally substituted saturated alkyl having from 1 to 10 carbon atoms, said optionally substituted unsaturated alkyl and optionally substituted saturated alkyl optionally containing a polar or charged functionality;
    or J is selected from the group consisting of an optionally substituted unsaturated acyl having from 1 to 18 carbon atoms and an optionally substituted saturated acyl having from 1 to 18 carbon atoms, said optionally substituted unsaturated acyl and optionally substituted saturated acyl optionally containing a polar or charged functionality; the process comprising:
    reacting a compound of Formula II,
    Figure US20070260087A1-20071108-C00014
    wherein Z1, Z2, Z3, Z4, Z5 and Z6 are as previously defined, with a compound of Formula III,
    Figure US20070260087A1-20071108-C00015
    wherein Y is R2 or NR2R5;
    R1, R2, R3 and R4 and R5 are independently selected from an optionally substituted C1-C10 alkyl or an optionally substituted C2-C10 alkenyl;
    R1 and R2 can optionally come together to form a ring;
    R3 and R4 can optionally come together to form a ring;
    and a compound selected from the group consisting of a saturated or unsaturated acyl halide, saturated or unsaturated carboxylic acid anhydride and a saturated or unsaturated activated carboxylic acid ester, all of which may optionally be substituted by one or more selected from the group consisting of protected hydroxy, alkyl, alkenyl, acyl, nitro, protected amino, amino, halo, protected carboxy and cyano; or a compound selected the group consisting of a saturated or unsaturated alkyl halide, saturated or unsaturated alkyl-O-sulfonyl alkyl, a saturated or unsaturated alkyl-O-sulfonyl aryl, a saturated or unsaturated alkyl-O-acyl, and a saturated or unsaturated epoxide, all of which may optionally be substituted by one or more selected from the group consisting of protected hydroxy, alkyl, alkenyl, acyl, nitro, protected amino, halo, protected carboxy, epoxide and cyano; and
    separating and isolating said compound of Formula I.
  • In a 2nd embodiment, the invention is represented by the process to manufacture a compound of Formula I or its ester or salt thereof,
    Figure US20070260087A1-20071108-C00016
    wherein Z1, Z2, Z3, and Z4 are independently selected from the group consisting of hydrogen and alkyl, said alkyl optionally substituted by hydroxy, alkyl, alkenyl, acyl, nitro, amino, halo, carboxy and cyano;
    Z5 and Z6 are the same or different and independently selected from the group consisting of alkyl, alkenyl, and aryl all of which can be optionally substituted by hydroxy, alkyl, alkenyl, acyl, nitro, amino, halo, carboxy and cyano;
    Z5 and Z6 can come together to form a carbocyclic ring;
    M is selected from the group consisting of hydrogen, an optionally substituted unsaturated alkyl having from 1 to 10 carbon atoms, and an optionally substituted saturated alkyl having from 1 to 10 carbon atoms, said optionally substituted unsaturated alkyl and optionally substituted saturated alkyl optionally containing a polar or charged functionality; and
    J is selected from the group consisting of an optionally substituted unsaturated alkyl having from 1 to 10 carbon atoms, and an optionally substituted saturated alkyl having from 1 to 10 carbon atoms, said optionally substituted unsaturated alkyl and optionally substituted saturated alkyl optionally containing a polar or charged functionality;
    the process comprising:
    reacting a compound of Formula II,
    Figure US20070260087A1-20071108-C00017
    wherein Z1, Z2, Z3, Z4, Z5 and Z6 are as previously defined,
    with a compound of Formula III,
    Figure US20070260087A1-20071108-C00018
    wherein Y is R2 or NR2R5;
    R1, R2, R3 and R4 and R5 are independently selected from an optionally substituted C1-C10 alkyl or an optionally substituted C2-C10 alkenyl;
    R1 and R2 can optionally come together to form a ring;
    R3 and R4 can optionally come together to form a ring;
    and a compound selected the group consisting of a saturated or unsaturated alkyl halide, saturated or unsaturated alkyl-O-sulfonyl alkyl, a saturated or unsaturated alkyl-O-sulfonyl aryl, a saturated or unsaturated alkyl-O-acyl, and a saturated or unsaturated epoxide, all of which may optionally be substituted by one or more selected from the group consisting of protected hydroxy, alkyl, alkenyl, acyl, nitro, protected amino, halo, protected carboxy, epoxide and cyano; and
    separating and isolating said compound of Formula I.
  • In a 3rd embodiment, the invention is represented by the process to manufacture a compound of Formula IV or its ester or salt thereof,
    Figure US20070260087A1-20071108-C00019
    wherein J is selected from the group consisting of an optionally substituted unsaturated alkyl having from 1 to 10 carbon atoms, and an optionally substituted saturated alkyl having from 1 to 10 carbon atoms, said optionally substituted unsaturated alkyl and optionally substituted saturated alkyl optionally containing a polar or charged functionality;
    the process comprising:
    reacting a compound of Formula V,
    Figure US20070260087A1-20071108-C00020
    with a compound of Formula III,
    Figure US20070260087A1-20071108-C00021
    wherein Y is R2 or NR2R5;
    R1, R2, R3 and R4 and R5 are independently selected from an optionally substituted C1-C10 alkyl or an optionally substituted C2-C10 alkenyl;
    R1 and R2 can optionally come together to form a ring;
    R3 and R4 can optionally come together to form a ring;
    and a compound selected from the group consisting of a saturated or unsaturated alkyl halide, saturated or unsaturated alkyl-O-sulfonyl alkyl, a saturated or unsaturated alkyl-O-sulfonyl aryl, a saturated or unsaturated alkyl-O-acyl, and a saturated or unsaturated epoxide, all of which may optionally be substituted by one or more substituents selected from the group consisting of protected hydroxy, alkyl, alkenyl, acyl, nitro, protected amino, halo, protected carboxy, epoxide and cyano; and separating and isolating said compound of Formula IV.
  • In a 4th embodiment, the invention is represented by the process to manufacture a compound of Formula I or its ester or salt thereof,
    Figure US20070260087A1-20071108-C00022
    wherein Z1, Z2, Z3, and Z4 are independently selected from the group consisting of hydrogen and alkyl, said alkyl optionally substituted by hydroxy, alkyl, alkenyl, acyl, nitro, amino, halo, carboxy and cyano;
    Z5 and Z6 are the same or different and independently selected from the group consisting of alkyl, alkenyl, and aryl all of which can be optionally substituted by hydroxy, alkyl, alkenyl, acyl, nitro, amino, halo, carboxy and cyano;
    Z5 and Z6 can come together to form a carbocyclic ring;
    M is selected from the group consisting of hydrogen, an optionally substituted unsaturated acyl having from 1 to 18 carbon atoms, and an optionally substituted saturated acyl having from 1 to 18 carbon atoms, said optionally substituted unsaturated acyl and optionally substituted saturated acyl optionally containing a polar or charged functionality; and
    J is selected from the group consisting of an optionally substituted unsaturated acyl having from 1 to 18 carbon atoms and an optionally substituted saturated acyl having from 1 to 18 carbon atoms, said optionally substituted unsaturated acyl and optionally substituted saturated acyl optionally containing a polar or charged functionality;
    the process comprising:
    reacting a compound of Formula II,
    Figure US20070260087A1-20071108-C00023
    wherein Z1, Z2, Z3, Z4, Z5 and Z6 are as previously defined,
    with a compound of Formula III,
    Figure US20070260087A1-20071108-C00024
    wherein Y is R2 or NR2R5;
    R1, R2, R3 and R4 and R5 are independently selected from an optionally substituted C1-C10 alkyl or an optionally substituted C2-C10 alkenyl;
    R1 and R2 can optionally come together to form a ring;
    R3 and R4 can optionally come together to form a ring;
    and a compound selected from the group consisting of a saturated or unsaturated acyl halide, saturated or unsaturated carboxylic acid anhydride and a saturated or unsaturated activated carboxylic acid ester, all of which may optionally be substituted by one or more substituents selected from the group consisting of protected hydroxy, alkyl, alkenyl, acyl, nitro, protected amino, amino, halo, protected carboxy and cyano; and
    separating and isolating said compound of Formula I.
  • In a 5th embodiment, the invention is represented by the process to manufacture a compound of Formula IV or its ester or salt thereof,
    Figure US20070260087A1-20071108-C00025
    wherein J is selected from the group consisting of an optionally substituted unsaturated acyl having from 1 to 18 carbon atoms and an optionally substituted saturated acyl having from 1 to 18 carbon atoms, said optionally substituted unsaturated acyl and optionally substituted saturated acyl optionally containing a polar or charged functionality;
    the process comprising:
    reacting a compound of Formula V,
    Figure US20070260087A1-20071108-C00026
    with a compound of Formula III,
    Figure US20070260087A1-20071108-C00027
    wherein Y is R2 or NR2R5;
    R1, R2, R3 and R4 and R5 are independently selected from an optionally substituted C1-C10 alkyl or an optionally substituted C2-C10 alkenyl;
    R1 and R2 can optionally come together to form a ring;
    R3 and R4 can optionally come together to form a ring;
    and a compound selected from the group consisting of a saturated or unsaturated acyl halide, saturated or unsaturated carboxylic acid anhydride and a saturated or unsaturated activated carboxylic acid ester, all of which may optionally be substituted by one or more substituents selected from the group consisting of protected hydroxy, alkyl, alkenyl, acyl, nitro, protected amino, amino, halo, protected carboxy and cyano; and
    separating and isolating said compound of Formula IV.
  • In a 6th embodiment, the invention is represented by the process to manufacture a compound of Formula IV or its ester or salt thereof,
    Figure US20070260087A1-20071108-C00028
    wherein J is selected from the group consisting of an optionally substituted unsaturated acyl having from 1 to 18 carbon atoms and an optionally substituted saturated acyl having from 1 to 18 carbon atoms, said optionally substituted unsaturated acyl and optionally substituted saturated acyl optionally containing a polar or charged functionality;
    the process comprising:
    reacting a compound of Formula V,
    Figure US20070260087A1-20071108-C00029
    with a compound of Formula VI,
    Figure US20070260087A1-20071108-C00030
    wherein R6 is selected from an optionally substituted C1-C10 alkyl or an optionally substituted C2-C10 alkenyl;
    m is an integer selected from 1 to 7;
    n is an integer selected from 1 to 7;
    and a compound selected from the group consisting of a saturated or unsaturated acyl halide, saturated or unsaturated carboxylic acid anhydride and a saturated or unsaturated activated carboxylic acid ester, all of which may optionally be substituted by one or more selected from the group consisting of protected hydroxy, alkyl, alkenyl, acyl, nitro, protected amino, amino, halo, protected carboxy and cyano; and separating and isolating said compound of Formula IV.
  • In a 7th embodiment, the invention is represented by the process to manufacture a compound of Formula IV or its ester or salt thereof,
    Figure US20070260087A1-20071108-C00031
    wherein J is selected from the group consisting of an optionally substituted unsaturated acyl having from 1 to 18 carbon atoms and an optionally substituted saturated acyl having from 1 to 18 carbon atoms, said optionally substituted unsaturated acyl and optionally substituted saturated acyl optionally containing a polar or charged functionality;
    the process comprising:
    reacting a compound of Formula V,
    Figure US20070260087A1-20071108-C00032
    with a compound of Formula VII,
    Figure US20070260087A1-20071108-C00033
    wherein m is an integer selected from 1 to 7;
    n is an integer selected from 1 to 7;
    and a compound selected from the group consisting of a saturated or unsaturated acyl halide, saturated or unsaturated carboxylic acid anhydride and a saturated or unsaturated activated carboxylic acid ester, all of which may optionally be substituted by one or more substituents selected from the group consisting of protected hydroxy, alkyl, alkenyl, acyl, nitro, protected amino, amino, halo, protected carboxy and cyano; and
    separating and isolating said compound of Formula IV.
  • In an 8th embodiment, the invention is represented by the process to manufacture a compound of Formula IV or its ester or salt thereof,
    Figure US20070260087A1-20071108-C00034
    wherein J is selected from the group consisting of an optionally substituted unsaturated acyl having from 1 to 18 carbon atoms and an optionally substituted saturated acyl having from 1 to 18 carbon atoms, said optionally substituted unsaturated acyl and optionally substituted saturated acyl optionally containing a polar or charged functionality;
    the process comprising:
    reacting a compound of Formula V,
    Figure US20070260087A1-20071108-C00035
    with a compound of Formula VII,
    Figure US20070260087A1-20071108-C00036
    wherein m is an integer selected from 1 to 7;
    n is an integer selected from 1 to 7;
    and a compound selected from the group consisting of succinic acid anhydride, glutaric acid anhydride, adipic acid anhydride, suberic acid anhydride, sebacic acid anhydride, azelaic acid anhydride, phthalic acid anhydride, maleic acid anhydride, and acetic acid anhydride, all of which may optionally be substituted by one or more substituents selected from the group consisting of protected hydroxy, alkyl, alkenyl, acyl, nitro, protected amino, halo, protected carboxy and cyano; and separating and isolating said compound of Formula IV.
  • In a 9th embodiment, the invention is represented by the process to manufacture a compound of Formula VIII, IX or X or its ester or salt thereof,
    Figure US20070260087A1-20071108-C00037
    the process comprising:
    reacting a compound of Formula V,
    Figure US20070260087A1-20071108-C00038
    with a compound of Formula VII,
    Figure US20070260087A1-20071108-C00039
    wherein m is an integer selected from 1 to 7;
    n is an integer selected from 1 to 7;
    and a compound selected from the group consisting of succinic acid anhydride, glutaric acid anhydride, and acetic acid anhydride, all of which may optionally be substituted by one or more substituents selected from the group consisting of protected hydroxy, alkyl, alkenyl, acyl, nitro, protected amino, halo, protected carboxy and cyano; and
    separating and isolating said compound of Formula VIII, IX or X.
  • In a 10th embodiment, the invention is represented by the process to manufacture a compound of Formula VIII, IX or X or its ester or salt thereof,
    Figure US20070260087A1-20071108-C00040
    the process comprising:
    reacting a compound of Formula V,
    Figure US20070260087A1-20071108-C00041
    with a compound of Formula DBU or DBN,
    Figure US20070260087A1-20071108-C00042
    and a compound selected from the group consisting of succinic acid anhydride, glutaric acid anhydride, and acetic acid anhydride, all of which may optionally be substituted by one or more substituents selected from the group consisting of protected hydroxy, alkyl, alkenyl, acyl, nitro, protected amino, halo, protected carboxy and cyano; and
    separating and isolating said compound of Formula VIII, IX or X.
  • In a 11th embodiment, the invention is represented by the process to manufacture a compound of Formula VIII or its ester or salt thereof,
    Figure US20070260087A1-20071108-C00043
    the process comprising:
    reacting a compound of Formula V
    Figure US20070260087A1-20071108-C00044
    with a compound of Formula DBU,
    Figure US20070260087A1-20071108-C00045
    and succinic acid anhydride;
    separating and isolating the compound of Formula VIII.
  • In a 12th embodiment, the invention is represented by the process to manufacture a compound of Formula VIII or its ester or salt thereof,
    Figure US20070260087A1-20071108-C00046
    the process comprising:
    reacting a compound of Formula V
    Figure US20070260087A1-20071108-C00047
    with DBU and succinic acid anhydride;
    Figure US20070260087A1-20071108-C00048
    further comprising the addition of an alkaline carbonate; and
    separating and isolating the compound of Formula VIII.
  • Further, while compositions and methods are described in terms of “comprising” various components or steps, the compositions and methods can also “consist essentially of” or “consist of” the various components and steps.
  • Suitable solvents for carrying out the processes of the present disclosure are inert organic solvents, including but are not limited to, alcohols, aldehydes, amides, ethers, esters, halogenated solvents, hydrocarbons, glycols and glycol ethers, ketones, nitrites, and numerous other solvents common in chemical processes, as well as mixtures of such solvents. These inert solvents can be used alone or in combination, and can be miscible or immiscible with each other.
    • Scheme
  • Scheme A as follows illustrates generally the process steps involved in the preparation of the compounds of the present invention. Unless otherwise indicated J, M, R1, R2, R3, R4, R5, Y, Z1, Z2, Z3, Z4, Z5, and Z6 in the reaction Scheme and the discussions that follow are defined as above.
    Figure US20070260087A1-20071108-C00049
    • EXAMPLES
  • The following are non-limiting examples of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventors to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the scope of the invention.
    • Example 1
  • In a dry 10 mL round bottom fitted with a nitrogen inlet, thermocouple and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous dimethylformamide. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the resulting solution was heated to 50° C. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.300 mL, 2.01 mmol) was added in 1 portion and the reaction was heated for an additional 1 h. Analysis by HPLC of the reaction mixture indicated 42% probucol monosuccinate, 6% probucol disuccinate, and 51% probucol by weight.
    • Example 2
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous dimethylformamide. Succinic anhydride (250 mg, 2.50 nmol) was added in 1 portion and the resulting solution was aged at room temperature. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.300 mL, 2.01 mmol) was added in 1 portion and the reaction was aged for an additional 1 h. Analysis by HPLC of the reaction mixture indicated 33% probucol monosuccinate, 5% probucol disuccinate, and 61% probucol by weight.
    • Example 3
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous acetonitrile. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the resulting solution was aged at room temperature. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.300 mL, 2.01 mmol) was added in I portion and the reaction was aged for an additional 1 h. Analysis by HPLC of the reaction mixture indicated 34% probucol monosuccinate, 7% probucol disuccinate, and 59% probucol by weight.
    • Example 4
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous tetrahydrofuran. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the resulting solution was aged at room temperature. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.300 mL, 2.01 mmol) was added in 1 portion and the reaction was aged for an additional 1 h. The reaction was slowly quenched with 1 N HCl, diluted with EtOAc and the phases were separated. Analysis by HPLC of the organic layer indicated 40% probucol monosuccinate, 8% probucol disuccinate, and 51% probucol by weight.
    • Example 5
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous 1,4-dioxane. Succinic anhydride (250 mg, 2.50 nmol) was added in 1 portion and the resulting solution was aged at room temperature. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.300 mL, 2.01 mmol) was added in 1 portion and the reaction was aged for an additional 1 h. The reaction was slowly quenched with 1 N HCl, diluted with EtOAc and the phases were separated. Analysis by HPLC of the organic layer indicated 41% probucol monosuccinate, 16% probucol disuccinate, and 43% probucol by weight.
    • Example 6
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous toluene. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the resulting solution was aged at room temperature. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.300 mL, 2.01 nmol) was added in 1 portion and the reaction was aged for an additional 1 h. The reaction was slowly quenched with 1 N HCl, diluted with EtOAc and the phases were separated. Analysis by HPLC of the organic layer indicated 32% probucol monosuccinate, 4% probucol disuccinate, and 64% probucol by weight.
    • Example 7
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous acetonitrile. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the resulting solution was aged at room temperature. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.075 mL, 0.50 mmol) was added in 1 portion and the reaction was aged for an additional 1 h. Analysis by HPLC of the reaction mixture indicated 15% probucol monosuccinate, 1% probucol disuccinate, and 83% probucol by weight.
    • Example 8
  • In a dry 10 mL round bottom fitted with a nitrogen inlet, thermocouple and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous acetonitrile. Succinic anhydride (250 mg, 2.50 nmol) was added in 1 portion and the resulting solution was heated to 50° C. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.075 mL, 0.50 mmol) was added in 1 portion and the reaction was heated for an additional 1 h. Analysis by HPLC of the reaction mixture indicated 20% probucol monosuccinate, 1% probucol disuccinate, and 79% probucol by weight.
    • Example 9
  • In a dry 10 mL round bottom fitted with a nitrogen inlet, thermocouple and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous acetonitrile. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the resulting solution was heated to 50° C. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.150 mL, 1.00 mmol) was added in 1 portion and the reaction was heated for an additional 1 h. Analysis by HPLC of the reaction mixture indicated 38% probucol monosuccinate, 7% probucol disuccinate, and 55% probucol by weight.
    • Example 10
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous dimethylformamide. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the resulting solution was aged at room temperature. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.075 mL, 0.50 mmol) was added in 1 portion and the reaction was aged for an additional 45 min. Analysis by HPLC of the reaction mixture indicated 12% probucol monosuccinate, 1% probucol disuccinate, and 87% probucol by weight.
    • Example 11
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous tetrahydrofuran. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the resulting solution was aged at room temperature. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.075 mL, 0.50 mmol) was added in 1 portion and the reaction was aged for an additional 45 min. The reaction was slowly quenched with 1 N HCl, diluted with EtOAc and NaCl and the phases were separated. Analysis by HPLC of the organic layer indicated 22% probucol monosuccinate, 2% probucol disuccinate, and 76% probucol by weight.
    • Example 12
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous 1,4-dioxane. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the resulting solution was aged at room temperature. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.075 mL, 0.50 mmol) was added in 1 portion and the reaction was aged for an additional 45 min. The reaction was slowly quenched with 1 N HCl, diluted with EtOAc and NaCl and the phases were separated. Analysis by HPLC of the organic layer indicated 24% probucol monosuccinate, 3% probucol disuccinate, and 73% probucol by weight.
    • Example 13
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous acetonitrile. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the resulting solution was aged at room temperature. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.150 mL, 1.00 nmol) was added in 1 portion and the reaction was aged for an additional 15 min. Analysis by HPLC of the reaction mixture indicated 25% probucol monosuccinate, 2% probucol disuccinate, and 73% probucol by weight.
    • Example 14
  • In a dry 10 mL round bottom fitted with a nitrogen inlet, thermocouple and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous tetrahydrofuran. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the resulting solution was heated to 50° C. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.150 mL, 1.00 mmol) was added in 1 portion and the reaction was heated for an additional 15 min. Analysis by HPLC of the reaction mixture indicated 29% probucol monosuccinate, 3% probucol disuccinate, and 68% probucol by weight.
    • Example 15
  • In a dry 10 mL round bottom fitted with a nitrogen inlet, thermocouple and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous dimethylformamide. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the resulting solution was heated to 50° C. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.150 mL, 1.00 mmol) was added in 1 portion and the reaction was heated for an additional 15 min. Analysis by HPLC of the reaction mixture indicated 28% probucol monosuccinate, 3% probucol disuccinate, and 69% probucol by weight.
    • Example 16
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous dimethylformamide. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.150 mL, 1.00 mmol) was added in 1 portion and the resulting solution was aged at room temperature. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the reaction was aged overnight. Analysis by HPLC of the reaction mixture indicated 25% probucol monosuccinate, 2% probucol disuccinate, and 73% probucol by weight.
    • Example 17
  • In a dry 10 mL round bottom fitted with a nitrogen inlet, thermocouple and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous dimethylformamide. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.150 mL, 1.00 mmol) was added in 1 portion and the resulting solution was heated to 50° C. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the reaction was heated overnight. Analysis by HPLC of the reaction mixture indicated 26% probucol monosuccinate, 2% probucol disuccinate, and 72% probucol by weight.
    • Example 18
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous acetonitrile. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.150 mL, 1.00 mmol) was added in 1 portion followed by an additional 2.5 mL of acetonitrile and the resulting solution was aged at room temperature. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the reaction was aged overnight. Analysis by HPLC of the reaction mixture indicated 37% probucol monosuccinate, 8% probucol disuccinate, and 55% probucol by weight.
    • Example 19
  • In a dry 10 mL round bottom fitted with a nitrogen inlet, thermocouple and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous acetonitrile. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.150 mL, 1.00 mmol) was added in 1 portion and the resulting solution was heated to 50° C. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the reaction was heated overnight. Analysis by HPLC of the reaction mixture indicated 44% probucol monosuccinate, 10% probucol disuccinate, and 46% probucol by weight.
    • Example 20
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous dimethylformamide. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.300 mL, 2.01 mmol) was added in 1 portion and the resulting solution was aged at room temperature. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the reaction was aged overnight. Analysis by HPLC of the reaction mixture indicated 40% probucol monosuccinate, 9% probucol disuccinate, and 51% probucol by weight.
    • Example 21
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 5.0 mL anhydrous acetonitrile. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.150 mL, 1.00 mmol) was added in 1 portion and the resulting solution was aged at room temperature. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the reaction was aged overnight. Analysis by HPLC of the reaction mixture indicated 43% probucol monosuccinate, 12% probucol disuccinate, and 45% probucol by weight.
    • Example 22
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 0.25 mL 1,1,3,3-tetramethylurea and 2.5 mL anhydrous acetonitrile. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.150 mL, 1.00 mmol) was added in 1 portion and the resulting solution was aged at room temperature. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the reaction was aged for an additional 2 h. Analysis by HPLC of the reaction mixture indicated 43% probucol monosuccinate, 11% probucol disuccinate, and 46% probucol by weight.
    • Example 23
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 0.25 mL 1,1,3,3-tetramethylurea and 2.5 mL anhydrous acetonitrile. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.150 mL, 1.00 mmol) was added in 1 portion and the resulting solution was aged at 50° C. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the reaction was heated for an additional 2 h. Analysis by HPLC of the reaction mixture indicated 48% probucol monosuccinate, 15% probucol disuccinate, and 37% probucol by weight.
    • Example 24
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 0.25 mL 1,1,3,3-tetramethylurea and 2.5 mL anhydrous dimethylformamide. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.150 mL, 1.00 mmol) was added in 1 portion and the resulting solution was aged at 50° C. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the reaction was heated for an additional 2 h. Analysis by HPLC of the reaction mixture indicated 34% probucol monosuccinate, 4% probucol disuccinate, and 62% probucol by weight.
    • Example 25
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 0.25 mL 1,1,3,3-tetramethylurea and 2.5 mL anhydrous 1,4-dioxane. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.150 mL, 1.00 mmol) was added in 1 portion and the resulting solution was aged at room temperature. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the reaction was aged for an additional 2 h. The reaction was slowly quenched with 1 N HCl, diluted with EtOAc and the phases were separated. Analysis by HPLC of the organic layer indicated 41% probucol monosuccinate, 13% probucol disuccinate, and 46% probucol by weight.
    • Example 26
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 0.25 mL 1,1,3,3-tetramethylurea and 2.5 mL anhydrous tetrahydrofuran. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.150 mL, 1.00 mmol) was added in 1 portion and the resulting solution was aged at room temperature. Succinic anhydride (250 mg, 2.50 nmol) was added in 1 portion and the reaction was aged for an additional 2 h. The reaction was slowly quenched with 1 N HCl, diluted with EtOAc and the phases were separated. Analysis by HPLC of the organic layer indicated 45% probucol monosuccinate, 15% probucol disuccinate, and 40% probucol by weight.
    • Example 27
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 0.25 mL 1,1,3,3-tetramethylurea and 1.0 mL anhydrous acetonitrile. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.150 mL, 1.00 mmol) was added in 1 portion and the resulting solution was aged at room temperature. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the reaction was aged for an additional 2 h. Analysis by HPLC of the reaction mixture indicated 45% probucol monosuccinate, 13% probucol disuccinate, and 42% probucol by weight.
    • Example 28
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 0.25 mL 1,1,3,3-tetramethylurea and 2.5 mL anhydrous 1,4-dioxane. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.150 mL, 1.00 mmol) was added in 1 portion and the resulting solution was aged at 50° C. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the reaction was heated for an additional 2 h. Analysis by HPLC of the reaction mixture indicated 42% probucol monosuccinate, 10% probucol disuccinate, and 48% probucol by weight.
    • Example 29
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 0.25 mL 1,1,3,3-tetramethylurea and 2.5 mL anhydrous tetrahydrofuran. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.150 mL, 1.00 mmol) was added in 1 portion and the resulting solution was aged at 50° C. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the reaction was heated for an additional 2 h. Analysis by HPLC of the reaction mixture indicated 43% probucol monosuccinate, 8% probucol disuccinate, and 49% probucol by weight.
    • Example 30
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 0.25 mL 1,1,3,3-tetramethylurea and 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.300 mL, 2.01 mmol) was added in 1 portion. To the reaction mixture was added 2.5 mL anhydrous acetone and the resulting solution was aged at room temperature. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the reaction was aged for an additional 2 h. Analysis by HPLC of the reaction mixture indicated 32% probucol monosuccinate, 5% probucol disuccinate, and 63% probucol by weight.
    • Example 31
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 0.25 mL 1,1,3,3-tetramethylurea and 5.0 mL anhydrous acetonitrile. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.300 mL, 2.01 mmol) was added in 1 portion and the resulting solution was aged at room temperature. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the reaction was aged for an additional 2 h. Analysis by HPLC of the reaction mixture indicated 44% probucol monosuccinate, 12% probucol disuccinate, and 44% probucol by weight.
    • Example 32
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 0.50 mL 1,1,3,3-tetramethylurea and 2.5 mL anhydrous acetonitrile. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.300 mL, 2.01 mmol) was added in 1 portion and the resulting solution was aged at room temperature. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the reaction was aged for an additional 2 h. Analysis by HPLC of the reaction mixture indicated 41% probucol monosuccinate, 9% probucol disuccinate, and 50% probucol by weight.
    • Example 33
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous acetonitrile. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the resulting solution was aged at room temperature. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.600 mL, 4.01 mmol) was added in 1 portion and the resulting solution was aged for an additional 1 h. Analysis by HPLC of the reaction mixture indicated 27% probucol monosuccinate, 5% probucol disuccinate, and 68% probucol by weight.
    • Example 34
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous acetonitrile. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the resulting solution was heated to 50° C. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.600 mL, 4.01 mmol) was added in 1 portion and the resulting solution was heated for an additional 1 h. Analysis by HPLC of the reaction mixture indicated 45% probucol monosuccinate, 5% probucol disuccinate, and 50% probucol by weight.
    • Example 35
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous acetonitrile. Succinic anhydride (250 mg, 2.50 mmol) was added in 1 portion and the resulting solution was heated to 50° C. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.300 mL, 2.01 mmol) was added in 1 portion and the resulting solution was heated for an additional 1 h. Analysis by HPLC of the reaction mixture indicated 49% probucol monosuccinate, 18% probucol disuccinate, and 33% probucol by weight.
    • Example 36
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous acetonitrile. Succinic anhydride (250 mg, 2.50 mmol) and 4-(dimethylamino)pyridine (60 mg, 0.49 mmol) were added and the resulting solution was heated to 50° C. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.300 mL, 2.01 mmol) was added in 1 portion and the resulting solution was heated for an additional 1 h. Analysis by HPLC of the reaction mixture indicated 49% probucol monosuccinate, 20% probucol disuccinate, and 31% probucol by weight.
    • Example 37
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous acetonitrile. Succinic anhydride (250 mg, 2.50 mmol) and 4-(dimethylamino)pyridine (250 mg, 2.05 mmol) were added and the resulting solution was heated to 50° C. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.075 mL, 0.50 mmol) was added in 1 portion and the resulting solution was heated for an additional 1 h. Analysis by HPLC of the reaction mixture indicated 25% probucol monosuccinate, 2% probucol disuccinate, and 73% probucol by weight.
    • Example 38
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous acetonitrile. Succinic anhydride (150 mg, 1.50 mmol) was added in 1 portion and the resulting solution was heated to 50° C. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.225 mL, 1.50 mmol) was added in 1 portion and the resulting solution was heated for an additional 2 h. Analysis by HPLC of the reaction mixture indicated 46% probucol monosuccinate, 11% probucol disuccinate, and 42% probucol by weight.
    • Example 39
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous acetonitrile. Succinic anhydride (250 mg, 2.50 nmol) was added in 1 portion and the resulting solution was heated to 50° C. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.225 mL, 1.50 mmol) was added in 1 portion and the resulting solution was heated for an additional 2 h. Analysis by HPLC of the reaction mixture indicated 46% probucol monosuccinate, 14% probucol disuccinate, and 40% probucol by weight.
    • Example 40
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 miol) followed by 2.5 mL anhydrous acetonitrile. Succinic anhydride (150 mg, 1.50 mmol) was added in 1 portion and the resulting solution was heated to 50° C. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.300 mL, 2.01 mmol) was added in 1 portion and the resulting solution was heated for an additional 2 h. Analysis by HPLC of the reaction mixture indicated 49% probucol monosuccinate, 10% probucol disuccinate, and 41% probucol by weight.
    • Example 41
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous acetonitrile. Succinic anhydride (150 mg, 1.50 mmol) was added in 1 portion and the resulting solution was heated to 50° C. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.150 mL, 1.00 mmol) was added in 1 portion and the resulting solution was heated for an additional 2 h. Analysis by HPLC of the reaction mixture indicated 44% probucol monosuccinate, 11% probucol disuccinate, and 45% probucol by weight.
    • Example 42
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous acetonitrile. Succinic anhydride (75 mg, 0.75 nmol) was added in 1 portion and the resulting solution was heated to 50° C. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.150 mL, 1.00 mmol) was added in 1 portion and the resulting solution was heated for an additional 2 h. Analysis by HPLC of the reaction mixture indicated 36% probucol monosuccinate, 5% probucol disuccinate, and 59% probucol by weight.
    • Example 43
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous acetonitrile. Succinic anhydride (75 mg, 0.75 mmol) was added in 1 portion and the resulting solution was heated to 50° C. 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.225 mL, 1.50 mmol) was added in 1 portion and the resulting solution was heated for an additional 2 h. Analysis by HPLC of the reaction mixture indicated 35% probucol monosuccinate, 3% probucol disuccinate, and 62% probucol by weight.
    • Example 44
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol), succinic anhydride (250 mg, 2.50 mmol), and K2CO3 (140 mg, 1.01 mmol) followed by 2.5 mL anhydrous dimethylformamide. The resulting reaction mixture was charged with 1,8-diazabicyclo[5.4.0]undec-7-ene (0.025 mL, 0.17 mmol) and aged overnight. Analysis by HPLC of the reaction mixture indicated 11% probucol monosuccinate, 1% probucol disuccinate, and 88% probucol by weight.
    • Example 45
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol), succinic anhydride (250 mg, 2.50 mmol), and Cs2CO3 (330 mg, 1.01 mmol) followed by 2.5 mL anhydrous dimethylformamide. The resulting reaction mixture was charged with 1,8-diazabicyclo[5.4.0]undec-7-ene (0.025 mL, 0.17 mmol) and aged overnight. Analysis by HPLC of the reaction mixture indicated 25% probucol monosuccinate, 2% probucol disuccinate, and 73% probucol by weight.
    • Example 46
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol), succinic anhydride (250 mg, 2.50 mmol), and K2CO3 (140 mg, 1.01 mmol) followed by 2.5 mL anhydrous acetonitrile. The resulting reaction mixture was charged with 1,8-diazabicyclo[5.4.0]undec-7-ene (0.025 mL, 0.17 mmol) and aged overnight. Analysis by HPLC of the reaction mixture indicated 7% probucol monosuccinate, <1% probucol disuccinate, and 93% probucol by weight.
    • Example 47
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol), succinic anhydride (250 mg, 2.50 mmol), and Cs2CO3 (330 mg, 1.01 mmol) followed by 2.5 mL anhydrous acetonitrile. The resulting reaction mixture was charged with 1,8-diazabicyclo[5.4.0]undec-7-ene (0.025 mL, 0.17 mmol) and aged overnight. Analysis by HPLC of the reaction mixture indicated 7% probucol monosuccinate, <1% probucol disuccinate, and 92% probucol by weight.
    • Example 48
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol), succinic anhydride (250 mg, 2.50 mmol), and K2CO3 (140 mg, 1.01 mmol) followed by 2.5 mL anhydrous dimethylformamide. The resulting reaction mixture was heated to 50° C. and then charged with 1,8-diazabicyclo[5.4.0]undec-7-ene (0.025 mL, 0.17 mmol) and heated overnight. Analysis by HPLC of the reaction mixture indicated 14% probucol monosuccinate, <1% probucol disuccinate, and 86% probucol by weight.
    • Example 49
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol), succinic anhydride (250 mg, 2.50 nmol), and Cs2CO3 (330 mg, 1.01 mmol) followed by 2.5 mL anhydrous dimethylformamide. The resulting reaction mixture was heated to 50° C. and then charged with 1,8-diazabicyclo[5.4.0]undec-7-ene (0.025 mL, 0.17 mmol) and heated for an additional 2 h. Analysis by HPLC of the reaction mixture indicated 19% probucol monosuccinate, 1% probucol disuccinate, and 80% probucol by weight.
    • Example 50
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol), succinic anhydride (250 mg, 2.50 mmol), and K2CO3 (140 mg, 1.01 mmol) followed by 2.5 mL anhydrous acetonitrile. The resulting reaction mixture was heated to 50° C. and then charged with 1,8-diazabicyclo[5.4.0]undec-7-ene (0.025 mL, 0.17 mmol) and heated overnight. Analysis by HPLC of the reaction mixture indicated 28% probucol monosuccinate, 3% probucol disuccinate, and 69% probucol by weight.
    • Example 51
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol), succinic anhydride (250 mg, 2.50 mmol), and Cs2CO3 (330 mg, 1.01 mmol) followed by 2.5 mL anhydrous acetonitrile. The resulting reaction mixture was heated to 50° C. and then charged with 1,8-diazabicyclo[5.4.0]undec-7-ene (0.025 mL, 0.17 mmol) and heated overnight. Analysis by HPLC of the reaction mixture indicated 40% probucol monosuccinate, 8% probucol disuccinate, and 52% probucol by weight.
    • Example 52
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol) followed by 2.5 mL anhydrous acetonitrile. Succinic anhydride (150 mg, 1.50 mmol) was added and the resulting solution was heated to 50° C. 1,5-Diazabicyclo[4.3.0]non-5-ene (0.180 mL, 0.15 nmol) was added and the solution was heated for an additional 1 h. Analysis by HPLC of the reaction mixture indicated 44% probucol monosuccinate, 9% probucol disuccinate, and 47% probucol by weight.
    • Example 53
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol), succinic anhydride (150 mg, 1.50 mmol), and Cs2CO3 (330 mg, 1.01 mmol) followed by 2.5 mL anhydrous acetonitrile. The resulting reaction mixture was heated to 50° C. and then charged with 1,8-diazabicyclo[5.4.0]undec-7-ene (0.075 mL, 0.50 mmol) and heated overnight. Analysis by HPLC of the reaction mixture indicated 42% probucol monosuccinate, 9% probucol disuccinate, and 49% probucol by weight.
    • Example 54
  • In a dry 10 mL round bottom fitted with a nitrogen inlet and stir bar was charged probucol (0.25 g, 0.48 mmol), succinic anhydride (150 mg, 1.50 mmol), and Cs2CO3 (330 mg, 1.01 mmol) followed by 2.5 mL anhydrous 2-butanone. The resulting reaction mixture was heated to 50° C. and then charged with 1,8-diazabicyclo[5.4.0]undec-7-ene (0.075 mL, 0.50 mmol) and heated overnight. Analysis by HPLC of the reaction mixture indicated 32% probucol monosuccinate, 4% probucol disuccinate, and 64% probucol by weight.
  • All of the processes disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. It will be apparent to those of skill in the art that variations may be applied to the methods described herein without departing from the concept and scope of the invention.

Claims (11)

1. A process of manufacturing a compound of Formula I or its ester or salt thereof,
Figure US20070260087A1-20071108-C00050
wherein Z1, Z2, Z3, and Z4 are independently selected from the group consisting of hydrogen and alkyl, said alkyl optionally substituted by hydroxy, alkyl, alkenyl, acyl, nitro, amino, halo, carboxy and cyano;
Z5 and Z6 are the same or different and independently selected from the group consisting of alkyl, alkenyl, and aryl all of which can be optionally substituted by hydroxy, alkyl, alkenyl, acyl, nitro, amino, halo, carboxy and cyano;
Z5 and Z6 can come together to form a carbocyclic ring;
M is selected from the group consisting of hydrogen, an optionally substituted unsaturated acyl having from 1 to 18 carbon atoms, and an optionally substituted saturated acyl having from 1 to 18 carbon atoms, said optionally substituted unsaturated acyl and optionally substituted saturated acyl optionally containing a polar or charged functionality; and
J is selected from the group consisting of an optionally substituted unsaturated acyl having from 1 to 18 carbon atoms and an optionally substituted saturated acyl having from 1 to 18 carbon atoms, said optionally substituted unsaturated acyl and optionally substituted saturated acyl optionally containing a polar or charged functionality;
the process comprising:
reacting a compound of Formula II
Figure US20070260087A1-20071108-C00051
wherein Z1, Z2, Z3, Z4, Z5 and Z6 are as previously defined,
with a compound of Formula III,
Figure US20070260087A1-20071108-C00052
wherein Y is R2 or NR2%5;
R1, R2, R3 and R4 and R5 are independently selected from an optionally substituted C1-C10 alkyl or an optionally substituted C2-C10 alkenyl;
R1 and R2 can optionally come together to form a ring;
R3 and R4 can optionally come together to form a ring;
and a compound selected from the group consisting of a saturated or unsaturated acyl halide, saturated or unsaturated carboxylic acid anhydride and a saturated or unsaturated activated carboxylic acid ester, all of which may optionally be substituted by one or more substituents selected from the group consisting of protected hydroxy, alkyl, alkenyl, acyl, nitro, protected amino, amino, halo, protected carboxy and cyano; and
separating and isolating the compound of Formula I.
2. The process of claim 1 to manufacture a compound of Formula IV or its ester or salt thereof,
Figure US20070260087A1-20071108-C00053
wherein J is selected from the group consisting of an optionally substituted unsaturated acyl having from 1 to 18 carbon atoms and an optionally substituted saturated acyl having from 1 to 18 carbon atoms, said optionally substituted unsaturated acyl and optionally substituted saturated acyl optionally containing a polar or charged functionality;
the process comprising:
reacting a compound of Formula V
Figure US20070260087A1-20071108-C00054
with a compound of Formula III,
Figure US20070260087A1-20071108-C00055
wherein Y is R2 or NR2R5;
R1, R2, R3 and R4 and R5 are independently selected from an optionally substituted C1-C10 alkyl or an optionally substituted C2-C10 alkenyl;
R1 and R2 can optionally come together to form a ring;
R3 and R4 can optionally come together to form a ring;
and a compound selected from the group consisting of a saturated or unsaturated acyl halide, saturated or unsaturated carboxylic acid anhydride and a saturated or unsaturated activated carboxylic acid ester, all of which may optionally be substituted by one or more substituents selected from the group consisting of protected hydroxy, alkyl, alkenyl, acyl, nitro, protected amino, amino, halo, protected carboxy and cyano; and
separating and isolating the compound of Formula IV.
3. The process of claim 1 to manufacture a compound of Formula IV or its ester or salt thereof,
Figure US20070260087A1-20071108-C00056
wherein J is selected from the group consisting of an optionally substituted unsaturated acyl having from 1 to 18 carbon atoms and an optionally substituted saturated acyl having from 1 to 18 carbon atoms, said optionally substituted unsaturated acyl and optionally substituted saturated acyl optionally containing a polar or charged functionality;
the process comprising:
reacting a compound of Formula V
Figure US20070260087A1-20071108-C00057
with a compound of Formula VI,
Figure US20070260087A1-20071108-C00058
wherein R6 is selected from an optionally substituted C1-C10 alkyl or an optionally substituted C2-C10 alkenyl;
m is an integer selected from 1 to 7;
n is an integer selected from 1 to 7;
and a compound selected from the group consisting of a saturated or unsaturated acyl halide, saturated or unsaturated carboxylic acid anhydride and a saturated or unsaturated activated carboxylic acid ester, all of which may optionally be substituted by one or more substituents selected from the group consisting of protected hydroxy, alkyl, alkenyl, acyl, nitro, protected amino, amino, halo, protected carboxy and cyano; and
separating and isolating said compound of Formula IV.
4. The process of claim 1 to manufacture a compound of Formula IV or its ester or salt thereof,
Figure US20070260087A1-20071108-C00059
wherein J is selected from the group consisting of an optionally substituted unsaturated acyl having from 1 to 18 carbon atoms and an optionally substituted saturated acyl having from 1 to 18 carbon atoms, said optionally substituted unsaturated acyl and optionally substituted saturated acyl optionally containing a polar or charged functionality;
the process comprising:
reacting a compound of Formula V
Figure US20070260087A1-20071108-C00060
with a compound of Formula VII,
Figure US20070260087A1-20071108-C00061
wherein m is an integer selected from 1 to 7;
n is an integer selected from 1 to 7;
and a compound selected from the group consisting of a saturated or unsaturated acyl halide, saturated or unsaturated carboxylic acid anhydride and a saturated or unsaturated activated carboxylic acid ester, all of which may optionally be substituted by one or more substituents selected from the group consisting of protected hydroxy, alkyl, alkenyl, acyl, nitro, protected amino, amino, halo, protected carboxy and cyano; and
separating and isolating said compound of Formula IV.
5. The process of claim 1 to manufacture a compound of Formula IV or its ester or salt thereof,
Figure US20070260087A1-20071108-C00062
wherein J is selected from the group consisting of an optionally substituted unsaturated acyl having from 1 to 18 carbon atoms and an optionally substituted saturated acyl having from 1 to 18 carbon atoms, said optionally substituted unsaturated acyl and optionally substituted saturated acyl optionally containing a polar or charged functionality;
the process comprising:
reacting a compound of Formula V
Figure US20070260087A1-20071108-C00063
with a compound of Formula VII,
Figure US20070260087A1-20071108-C00064
wherein m is an integer selected from 1 to 7;
n is an integer selected from 1 to 7;
and a compound selected from the group consisting of succinic acid anhydride, glutaric acid anhydride, adipic acid anhydride, suberic acid anhydride, sebacic acid anhydride, azelaic acid anhydride, phthalic acid anhydride, maleic acid anhydride, and acetic acid anhydride, all of which may optionally be substituted by one or more substituents selected from the group consisting of protected hydroxy, alkyl, alkenyl, acyl, nitro, protected amino, halo, protected carboxy and cyano; and
separating and isolating said compound of Formula IV.
6. The process of claim 1 to manufacture a compound of Formula VIII, IX or X or its ester or salt thereof,
Figure US20070260087A1-20071108-C00065
the process comprising:
reacting a compound of Formula V
Figure US20070260087A1-20071108-C00066
with a compound of Formula VII,
Figure US20070260087A1-20071108-C00067
wherein m is an integer selected from 1 to 7;
n is an integer selected from 1 to 7;
and a compound selected from the group consisting of succinice acid anhydride, glutaric acid anhydride, and acetic acid anhydride, all of which may optionally be substituted by one or more substituents selected from the group consisting of protected hydroxy, alkyl, alkenyl, acyl, nitro, protected amino, halo, protected carboxy and cyano; and
separating and isolating said compound of Formula VIII, IX or X.
7. The process of claim 1 to manufacture a compound of Formula VIII, IX or X or its ester or salt thereof,
Figure US20070260087A1-20071108-C00068
the process comprising:
reacting a compound of Formula V
Figure US20070260087A1-20071108-C00069
with a compound of Formula DBU or DBN,
Figure US20070260087A1-20071108-C00070
and a compound selected from the group consisting of succinic acid anhydride, glutaric acid anhydride, and acetic acid anhydride, all of which may optionally be substituted by one or more substituents selected from the group consisting of protected hydroxy, alkyl, alkenyl, acyl, nitro, protected amino, halo, protected carboxy and cyano; and
separating and isolating said compound of Formula VIII, IX or X.
8. The process of claim 1 to manufacture a compound of Formula VIII or its ester or salt thereof,
Figure US20070260087A1-20071108-C00071
the process comprising:
reacting a compound of Formula V
Figure US20070260087A1-20071108-C00072
with a compound of Formula DBU,
Figure US20070260087A1-20071108-C00073
and succinic acid anhydride; and
separating and isolating said compound of Formula VIII.
9. The process of claim 1 to manufacture a compound of Formula VIII or its ester or salt thereof,
Figure US20070260087A1-20071108-C00074
the process comprising:
reacting a compound of Formula V
Figure US20070260087A1-20071108-C00075
with a compound of Formula DBU,
Figure US20070260087A1-20071108-C00076
and succinic acid anhydride;
and further comprising the addition of an alkaline carbonate; and
separating and isolating said compound of Formula VIII.
10. A process for manufacturing a compound of Formula I or its ester or salt thereof,
Figure US20070260087A1-20071108-C00077
wherein Z1, Z2, Z3, and Z4 are independently selected from the group consisting of hydrogen and alkyl, said alkyl optionally substituted by hydroxy, alkyl, alkenyl, acyl, nitro, amino, halo, carboxy and cyano;
Z5 and Z6 are the same or different and independently selected from the group consisting of alkyl, alkenyl, and aryl all of which can be optionally substituted by hydroxy, alkyl, alkenyl, acyl, nitro, amino, halo, carboxy and cyano;
Z5 and Z6 can come together to form a carbocyclic ring;
M is selected from the group consisting of hydrogen, an optionally substituted unsaturated alkyl having from 1 to 10 carbon atoms, and an optionally substituted saturated alkyl having from 1 to 10 carbon atoms, said optionally substituted unsaturated alkyl and optionally substituted saturated alkyl optionally containing a polar or charged functionality; and
J is selected from the group consisting of an optionally substituted unsaturated alkyl having from 1 to 10 carbon atoms, and an optionally substituted saturated alkyl having from 1 to 10 carbon atoms, said optionally substituted unsaturated alkyl and optionally substituted saturated alkyl optionally containing a polar or charged functionality;
the process comprising:
reacting a compound of Formula II
Figure US20070260087A1-20071108-C00078
wherein Z1, Z2, Z3, Z4, Z5 and Z6 are as previously defined,
with a compound of Formula III,
Figure US20070260087A1-20071108-C00079
wherein Y is R2 or NR2R5;
R1, R2, R3 and R4 and R5 are independently selected from an optionally substituted C1-C10 alkyl or an optionally substituted C2-C10 alkenyl;
R1 and R2 can optionally come together to form a ring;
R3 and R4 can optionally come together to form a ring;
and a compound selected the group consisting of a saturated or unsaturated alkyl halide, saturated or unsaturated alkyl-O-sulfonyl alkyl, a saturated or unsaturated alkyl-O-sulfonyl aryl, a saturated or unsaturated alkyl-O-acyl, and a saturated or unsaturated epoxide, all of which may optionally be substituted by one or more substituents selected from the group consisting of protected hydroxy, alkyl, alkenyl, acyl, nitro, protected amino, halo, protected carboxy, epoxide and cyano; and
separating and isolating the compound of Formula I.
11. The process of claim 10 to manufacture a compound of Formula IV or its ester or salt thereof,
Figure US20070260087A1-20071108-C00080
wherein J is selected from the group consisting of an optionally substituted unsaturated alkyl having from 1 to 10 carbon atoms, and an optionally substituted saturated alkyl having from 1 to 10 carbon atoms, said optionally substituted unsaturated alkyl and optionally substituted saturated alkyl optionally containing a polar or charged functionality;
the process comprising:
reacting a compound of Formula V
Figure US20070260087A1-20071108-C00081
with a compound of Formula III,
Figure US20070260087A1-20071108-C00082
wherein Y is R1 or NR2R5;
R1, R2, R3 and R4 and R5 are independently selected from an optionally substituted C1-C10 alkyl or an optionally substituted C2-C10 alkenyl;
R1 and R2 can optionally come together to form a ring;
R3 and R4 can optionally come together to form a ring;
and a compound selected from the group consisting of a saturated or unsaturated alkyl halide, saturated or unsaturated alkyl-O-sulfonyl alkyl, a saturated or unsaturated alkyl-O-sulfonyl aryl, a saturated or unsaturated alkyl-O-acyl, and a saturated or unsaturated epoxide, all of which may optionally be substituted by one or more substituents selected from the group consisting of protected hydroxy, alkyl, alkenyl, acyl, nitro, protected amino, halo, protected carboxy, epoxide and cyano; and
separating and isolating the compound of Formula IV.
US11/578,871 2004-04-20 2005-04-20 Process of Preparing Esters and Ethers of Probucol and Derivatives Thereof Abandoned US20070260087A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/578,871 US20070260087A1 (en) 2004-04-20 2005-04-20 Process of Preparing Esters and Ethers of Probucol and Derivatives Thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56426704P 2004-04-20 2004-04-20
US11/578,871 US20070260087A1 (en) 2004-04-20 2005-04-20 Process of Preparing Esters and Ethers of Probucol and Derivatives Thereof
PCT/US2005/013394 WO2005102323A2 (en) 2004-04-20 2005-04-20 Process of preparing esters and ethers of probucol and derivatives thereof

Publications (1)

Publication Number Publication Date
US20070260087A1 true US20070260087A1 (en) 2007-11-08

Family

ID=35197488

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/578,871 Abandoned US20070260087A1 (en) 2004-04-20 2005-04-20 Process of Preparing Esters and Ethers of Probucol and Derivatives Thereof
US11/111,194 Expired - Fee Related US7294737B2 (en) 2004-04-20 2005-04-20 Process of preparing esters and ethers of probucol and derivatives thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/111,194 Expired - Fee Related US7294737B2 (en) 2004-04-20 2005-04-20 Process of preparing esters and ethers of probucol and derivatives thereof

Country Status (2)

Country Link
US (2) US20070260087A1 (en)
WO (1) WO2005102323A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4467429B2 (en) * 2002-07-12 2010-05-26 アセロジエニクス・インコーポレイテツド Novel salt forms of low-soluble probucol esters and ethers
CN100548950C (en) * 2003-01-13 2009-10-14 阿特罗吉尼克斯公司 Preparation probucol and the ester of derivative and the method for ether
WO2005102323A2 (en) * 2004-04-20 2005-11-03 Atherogenics, Inc. Process of preparing esters and ethers of probucol and derivatives thereof
EP1874725A4 (en) * 2005-04-21 2011-04-06 Atherogenics Inc Process for the separation of probucol derivatives
CN108299263B (en) * 2018-01-30 2020-12-01 北京德默高科医药技术有限公司 Probucol derivative and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7294737B2 (en) * 2004-04-20 2007-11-13 Atherogenics, Inc. Process of preparing esters and ethers of probucol and derivatives thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3179701A (en) 1962-05-14 1965-04-20 Shell Oil Co (3, 5-dialkyl-4-hydroxyphenyl) (3, 5-dialkyl-4-hydroxybenzyl) sulfides
GB1136539A (en) 1966-12-13 1968-12-11 Uniroyal Inc Phenolic sulphides
GB1199871A (en) 1967-05-11 1970-07-22 Consolidation Coal Co Improvements in or relating to Sulfur-Containing Bisphenols
US3485843A (en) 1967-05-11 1969-12-23 Dow Chemical Co Piperazine adducts of ketone mercaptoles
GB1148550A (en) 1967-12-02 1969-04-16 Uniroyal Inc Substituted benzylphenyl sulfides and their use as antioxidants
US3576883A (en) 1969-06-30 1971-04-27 Consolidation Coal Co Alkylidenedithiobisphenols
FR2130975A5 (en) 1971-03-29 1972-11-10 Aries Robert Bis(4-(phenoxyalkanoyloxy)-phenylthio)alkanes - hypolipemics hypocholesterolemics
FR2133024A5 (en) 1971-04-06 1972-11-24 Aries Robert Bis-(4-nicotinoyloxyphenylthio) propanes - with hypocholesterolaemic and hypolipaemic activity
FR2134810A5 (en) 1971-04-21 1972-12-08 Aries Robert Bis-(3-alkyl-5-t-alkyl-4-(thiazole-5-carboxy)phenylthio) alcanes - - with hypocholesterolaemic and hypolipaemic activity
FR2140769A5 (en) 1971-06-07 1973-01-19 Aries Robert Benzofuryloxy alkanoic derivs of probucol - hypocholesterolemic and hypolipemic agents
FR2140771A5 (en) 1971-06-07 1973-01-19 Aries Robert Tetralinyl phenoxy alkanoic esters - of bis hydroxyphenylthio alkanes, hypolipemics etc
US3704327A (en) 1971-12-10 1972-11-28 Continental Oil Co Alkylidenedithio-bisphenols
US3897500A (en) 1971-12-10 1975-07-29 Continental Oil Co Alkylidenedithiobisphenols
FR2168137A1 (en) 1972-01-17 1973-08-31 Dynachim Sarl Bis 4-hydroxyphenylthioalkane esters - with hypocholesterolaemic and hypolipaemic activities
US3952064A (en) 1973-03-12 1976-04-20 Crown Zellerbach Corporation Process for producing mercaptophenols
US4029812A (en) 1976-02-18 1977-06-14 The Dow Chemical Company Novel hypolipidemic 2-(3,5-di-tert-butyl-4-hydroxyphenyl)thio carboxamides
JPS52125170A (en) 1976-04-12 1977-10-20 Yoshitomi Pharmaceut Ind Ltd Pyridine derivatives
EP0190682B1 (en) 1985-02-04 1990-09-12 G.D. Searle & Co. Novel disubstituted 4-hydroxyphenylthio anilides
US4755524A (en) 1986-01-31 1988-07-05 G. D. Searle & Co. Novel phenolic thioethers as inhibitors of 5-lipoxygenase
US4734527A (en) 1986-10-17 1988-03-29 Merrell Dow Pharmaceuticals Inc. Process for preparing 2,6-di-tertiarybutyl-4-mercaptophenol
US4752616A (en) 1987-06-29 1988-06-21 E. R. Squibb & Sons, Inc. Arylthioalkylphenyl carboxylic acids, compositions containing same and method of use
NZ226621A (en) 1987-11-13 1991-12-23 Riker Laboratories Inc Di-tert butyl phenols substituted by alkoxy, benzyloxy, or benzylthio groups; pharmaceutical compositions containing them
JP2754039B2 (en) 1988-06-24 1998-05-20 塩野義製薬株式会社 Di-tert-butylhydroxyphenylthio derivative
JP2627003B2 (en) 1989-01-25 1997-07-02 塩野義製薬株式会社 G-tert-butylhydroxyphenylthio derivative
JP3065636B2 (en) 1989-06-29 2000-07-17 塩野義製薬株式会社 [Di-tert-butyl (hydroxy) phenylthio] substituted hydroxamic acid derivatives
DE3929913A1 (en) 1989-09-08 1991-04-04 Hoechst Ag 4-HYDROXYTETRAHYDROPYRAN-2-ONE AND THE CORRESPONDING DIHYDROXYCARBONSAEUREDERIVATES, SALTS AND ESTERS, PROCESS FOR THEIR PREPARATION, THEIR USE AS A MEDICAMENT, PHARMACEUTICAL PREPARATES AND PREPARED PRODUCTS
US5155250A (en) 1990-07-05 1992-10-13 Merrell Dow Pharmaceuticals Inc. 2,6-di-alkyl-4-silyl-phenols as antiatheroscerotic agents
FR2666583B1 (en) 1990-09-06 1994-09-09 Adir NOVEL DERIVATIVES OF SPIRO [4.5] DECANE, THEIR PREPARATION PROCESS AND THEIR PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5262439A (en) * 1992-04-30 1993-11-16 The Regents Of The University Of California Soluble analogs of probucol
FR2704224B1 (en) 1993-04-20 1995-08-25 Adir New acids and substituted isobutyric phenoxy esters.
US5635514A (en) 1994-10-25 1997-06-03 G. D. Searle & Company Heteroaralkyl and heteroarylthioalkyl thiophenolic compounds as 5-lipoxgenase inhibitors
FR2738817B1 (en) 1995-09-14 1997-10-17 Adir NOVEL SUBSTITUTED ALKANOIC 2,2-DIMETHYL-OMEGA-PHENOXY ACIDS AND ESTERS, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO1997015546A1 (en) 1995-10-26 1997-05-01 Nippon Shinyaku Co., Ltd. Carboxylic acid derivatives and pharmaceutical compositions
US5608095A (en) 1996-04-30 1997-03-04 Hoechst Marion Roussel, Inc. Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents
PT942896E (en) 1996-11-20 2003-07-31 Aventis Pharma Inc UTILIZED SUBSTITUTED PHENOIS AND THIOFENOES AS ANTIOXIDANT AGENTS
US6670398B2 (en) 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
US6852878B2 (en) 1998-05-14 2005-02-08 Atherogenics, Inc. Thioketals and thioethers for inhibiting the expression of VCAM-1
CN1275596C (en) 1997-05-14 2006-09-20 阿特罗吉尼克斯公司 Application of probuco monoester intreating amgiocardiopathy and inflammatry disease
AU1387399A (en) 1997-11-10 1999-05-31 Vyrex Corporation Probucol esters and uses thereof
DE19850532A1 (en) 1998-11-03 2000-05-04 Nematel Dr Rudolf Eidenschink Bisphenylthio compounds
ATE326014T1 (en) 1998-11-09 2006-06-15 Atherogenics Inc METHOD AND COMPOSITIONS FOR REDUCING PLASMA CHOLESTEROL LEVELS
CA2403490A1 (en) 2000-03-21 2001-10-25 Atherogenics, Inc. N-substituted dithiocarbamates for the treatment of biological disorders
JP2003528109A (en) 2000-03-21 2003-09-24 アセロジエニクス・インコーポレイテツド Thioketals and thioethers for inhibiting the expression of VCAM-1
CA2404044A1 (en) 2000-04-11 2001-10-18 Atherogenics, Inc. Compounds and methods to increase plasma hdl cholesterol levels and improve hdl functionality
US6323359B1 (en) * 2000-05-02 2001-11-27 Salsbury Chemicals, Inc. Process for preparing probucol derivatives
ITMI20020597A1 (en) * 2002-03-22 2003-09-22 Nicox Sa DERIVATIVES OF THE PROBUCLE
JP4467429B2 (en) 2002-07-12 2010-05-26 アセロジエニクス・インコーポレイテツド Novel salt forms of low-soluble probucol esters and ethers
CN100548950C (en) 2003-01-13 2009-10-14 阿特罗吉尼克斯公司 Preparation probucol and the ester of derivative and the method for ether

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7294737B2 (en) * 2004-04-20 2007-11-13 Atherogenics, Inc. Process of preparing esters and ethers of probucol and derivatives thereof

Also Published As

Publication number Publication date
US7294737B2 (en) 2007-11-13
WO2005102323A3 (en) 2005-12-15
US20050267187A1 (en) 2005-12-01
WO2005102323A2 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
US7294737B2 (en) Process of preparing esters and ethers of probucol and derivatives thereof
EP0541550B1 (en) New intermediates, their production and use
BRPI0612475A2 (en) methods for preparing a compound
CS271469B2 (en) Method of phenoxyalkylcarboxyl acid&#39;s derivatives production
Alferiev et al. A novel mercapto-bisphosphonate as an efficient anticalcification agent for bioprosthetic tissues
JP2019199446A (en) Method of producing s-ica ribosylhomocysteine
EP1366013B1 (en) A process for the preparation of fibrates
DE60108112T2 (en) Process for the preparation of carbostyrene derivatives
DK147197B (en) ANALOGY PROCEDURE FOR PREPARING 2-HYDRAZONEOPROPIONIC ACID DERIVATIVES
US4609673A (en) Carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
KR950014792B1 (en) Benzimidazole derivatives and process for their preparations
AU623373B2 (en) Metabolites of pentanedioic acid derivatives
US7687659B2 (en) Process for the separation of probucol derivatives
JP4210573B2 (en) Substituted phenoxypropanolamines
US20130005995A1 (en) Method for preparing a fatty acid derivative
SU534182A3 (en) Method for preparing sulfur-containing trialkoxybenzoylaminocarboxylic acid derivatives or their salts
EP0627403B1 (en) Method for the production of hydroxyphenylacetic acids
US3201475A (en) Bisglyoxalyldiphenyl derivatives
EP0802193B1 (en) Process for the preparation of substituted pyrimidines
US7247744B2 (en) Process for the preparation of probucol derivatives
PT91036B (en) PROCESS FOR THE PREPARATION OF SULFONYL-INDOLIZIN DERIVATIVES, UTEIS AS SYNTHESIS INTERMEDIARIES
JPS60185761A (en) 7-thiaprostaglandin e1 compound and its preparation
JPH10130245A (en) Production of acyclonucleoside
CS224628B2 (en) Method for producing 4-thia-pgi 1,4-sulphinyl-pgi 1 and derivates thereof
CZ170697A3 (en) Process for preparing £(5,6-dicarboxy-3-pyridyl)methyl|ammonium halide

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION